Inhibitors in mild/moderate haemophilia A: an update.

Abstract excerpt

The development of inhibitors in patients with mild/moderate hemophilia A is an increasingly recognized occurrence and is manifested by the patients' bleeding pattern becoming more severe. Inherited (hemophilia genetic mutations) and acquired (type and delivery of factor VIII replacement therapy) factors have been associated with an increased likelihood of developing factor VIII inhibitors. Although the use of...

Topics

Join the communities discussing this publication.

• Blood Coagulation Factors
• Factor VIII
• Genetic Predisposition to Disease
• Hemophilia A
• Risk